Yang S, et al. - Since alternative chemotherapy regimens were proposed to increase efficacy (e.g. R-ACVBP) or decrease toxicity e.g. R-CE(Etoposide)OP, with conflicting results, researchers examined how the R-CEpiVDSP regimen frequently used in China performs in comparison to R-CHOP, standard first-line therapy for patients with diffuse large B-cell lymphoma (DLBCL). For this investigation, the outcome of consecutive DLBCL patients was analyzed (aged 61-80 years) treated between May 2009 and April 2018 at People`s hospital, a tertiary referral center in Beijing, China. Study participants received first-line therapy with rituximab (375 mg/m<sup>2</sup>), cyclophosphamide (750 mg/m<sup>2</sup>), epirubicin (60 mg/m<sup>2</sup>) instead of doxorubicin, vindesine (2 mg/m<sup>2</sup>) instead of vincristine, and prednisone (100mg, days 1-5). In this analysis, 58 patients from People`s Hospital, Peking University, and 243 patients were involved. The authors found no significant differences in progression-free survival or overall survival between patients treated with 6 (8) x R-CEpiVDSP in China or 6 (8) x R-CHOP-14 administered to elderly patients within the RICOVER-60 trial. Both regimens gave positive outcomes given the age and frequency of patients with IPI >2. The R-CEpiVDSP regimen represents a valuable alternative to R-CHOP with comparable efficacy and potentially less cardiac and neurological toxicity in elderly patients with preexisting cardiac disease or neuropathy.